Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — November 2013

Planlagt Fastgjort Låst Flyttet Genmab
226 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • J Offline
    J Offline
    JKY_VH
    wrote on sidst redigeret af
    #92

    Tak gentogen.

    1 Reply Last reply
    0
    • JørgenVarnæsJ Offline
      JørgenVarnæsJ Offline
      JørgenVarnæs
      wrote on sidst redigeret af
      #93

      Det er en forbavsende styrke GEN viser i dag. Mon vi har vendt faldet ryggen og går ind i en ny fase nu?

      1 Reply Last reply
      0
      • SolsenS Offline
        SolsenS Offline
        Solsen
        wrote on sidst redigeret af
        #94

        Tror vi skal en eller to uger frem før der købes op mhb på gode ash nyheder. Inden da kan en test af 200 sagtens ske.

        1 Reply Last reply
        0
        • G Offline
          G Offline
          gentogen
          wrote on sidst redigeret af
          #95

          Complement Activations through IgG Hexamers
          Complement activation by antibodies represents a potent form of immune defense. By using cryo-electron tomography and mutagenesis studies we reveal the molecular mechanism by which antibody complexed to antigen triggers complement activation. Our data provide a model for understanding complement activation by antibodies and provides leads for its modulation.
          Janine Schuurman, Ph.D., Director, Strategic Research, Genmab B.V., The Netherlands

          1 Reply Last reply
          0
          • G Offline
            G Offline
            gentogen
            wrote on sidst redigeret af
            #96

            Muligvis gammelt nyt. Der er så meget pt...http://www.ibclifesciences.com/AntibodyEng/agenda.xml

            1 Reply Last reply
            0
            • investor1989I Offline
              investor1989I Offline
              investor1989
              wrote on sidst redigeret af
              #97

              Carnegie har en rigtig god pointe omkring Genmab. med over 30+% af patienter med Gazyva der har grade 3´+ infusion eller neutropenia events vil en meget stor del af de patienter nok stoppe med Gazyva og gå Arzerra eller Rituxan

              1 Reply Last reply
              0
              • investor1989I Offline
                investor1989I Offline
                investor1989
                wrote on sidst redigeret af
                #98

                Så selv hvis Gazyva bliver lægernes første valg, vil en stor af patienterne nok indse at de ikke kan tåle Gazyva og skifte behandling ?

                1 Reply Last reply
                0
                • G Offline
                  G Offline
                  gentogen
                  wrote on sidst redigeret af
                  #99

                  I patienter uden NOTCH1 mutation er PFS 23,3 for OC kombinationen https://ash.confex.com/ash/2013/webprogram/Paper58266.html

                  1 Reply Last reply
                  0
                  • G Offline
                    G Offline
                    gentogen
                    wrote on sidst redigeret af
                    #100

                    I øvrigt er jeg helt enig i det foregående. Og hvis Gazyva vælges fra, så er Arzerra nærliggende, da det jo ser ud til at være bedre end Ritux på alle parametre

                    1 Reply Last reply
                    0
                    • SolsenS Offline
                      SolsenS Offline
                      Solsen
                      wrote on sidst redigeret af
                      #101

                      19% gennemførte ikke behandlingsforløbet med Gazyva. Altså hver femte pts måtte afbryde ! (Lige som jeg husker)

                      1 Reply Last reply
                      0
                      • SolsenS Offline
                        SolsenS Offline
                        Solsen
                        wrote on sidst redigeret af
                        #102

                        Første behandling over to dage og groft sagt livsfarligt !

                        1 Reply Last reply
                        0
                        • G Offline
                          G Offline
                          gentogen
                          wrote on sidst redigeret af
                          #103

                          Ja. The first dose of GAZYVA was divided between day 1 (100 mg) and day 2 (900 mg) [see Dosage and Administration (2.1)], which was implemented in 45 patients.

                          1 Reply Last reply
                          0
                          • G Offline
                            G Offline
                            gentogen
                            wrote on sidst redigeret af
                            #104

                            PML has been reported with GAZYVA

                            1 Reply Last reply
                            0
                            • G Offline
                              G Offline
                              gentogen
                              wrote on sidst redigeret af
                              #105

                              Fatal cardiac events have been reported in patients treated with GAZYVA

                              1 Reply Last reply
                              0
                              • G Offline
                                G Offline
                                gentogen
                                wrote on sidst redigeret af
                                #106

                                Hepatitis B virus reactivation has been reported with GAZYVA

                                1 Reply Last reply
                                0
                                • G Offline
                                  G Offline
                                  gentogen
                                  wrote on sidst redigeret af
                                  #107

                                  http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125486s000lbl.pdf

                                  1 Reply Last reply
                                  0
                                  • G Offline
                                    G Offline
                                    gentogen
                                    wrote on sidst redigeret af
                                    #108

                                    Den sidste er dog ikke kun for G, men alligevel...

                                    1 Reply Last reply
                                    0
                                    • G Offline
                                      G Offline
                                      gentogen
                                      wrote on sidst redigeret af
                                      #109

                                      Roche: At the data cut-off, 9%, 15%, and 20% of the patients in the GClb, RClb, and Clb arms, respectively, had died.

                                      1 Reply Last reply
                                      0
                                      • G Offline
                                        G Offline
                                        gentogen
                                        wrote on sidst redigeret af
                                        #110

                                        Ofatumumab: Deaths during treatment occurred in 2% of subjects in both arms

                                        1 Reply Last reply
                                        0
                                        • SolsenS Offline
                                          SolsenS Offline
                                          Solsen
                                          wrote on sidst redigeret af
                                          #111

                                          Kapitalforhøjelse i Genmab

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger